Lilly’s Foundayo, Zepbound Gain PBM Coverage with $25 Monthly Co-Pay
LLY•CVS Caremark will cover Lilly's oral GLP-1 pill Foundayo June 1 and restore Zepbound coverage by October 1, enabling eligible patients to pay as little as $25 monthly. Medicare Part D beneficiaries may also access both drugs for $50 per month through the GLP-1 Bridge program starting July 1.
1. PBM Coverage Expansion
Lilly has secured coverage for its obesity portfolio from all three largest PBMs, with CVS Caremark set to include Foundayo on its commercial formulary June 1 and restore Zepbound coverage by October 1. This milestone ensures broad access across major health plans and plan templates nationwide.
2. Patient Cost and Eligibility
Eligible commercially insured patients may pay as little as $25 per month for either Foundayo or Zepbound, while Medicare Part D beneficiaries can secure coverage at $50 monthly through the GLP-1 Bridge program beginning July 1. The programs eliminate prior financial barriers for millions of patients with obesity.
3. Drug Details and Impact
Foundayo offers the convenience of a once-daily oral GLP-1 receptor agonist without food or water restrictions, while Zepbound remains the most-prescribed injectable for weight management. Expanded coverage is poised to drive adoption rates and support Lilly’s market leadership in obesity treatment.
